INFLUENCE OF APO-E POLYMORPHISM ON THE RESPONSE TO SIMVASTATIN TREATMENT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

被引：0
|
作者：
DEKNIJFF, P
STALENHOEF, AFH
MOL, MJTM
LEUVEN, JAG
SMIT, J
ERKELENS, DW
SCHOUTEN, J
FRANTS, RR
HAVEKES, LM
机构：
[1] TNO, GAUBIUS INST, POB 612, 2300 AP LEIDEN, NETHERLANDS
[2] UNIV HOSP NIJMEGEN, DEPT MED, DIV GEN INTERNAL MED, NIJMEGEN, NETHERLANDS
[3] STATE UNIV UTRECHT HOSP, DEPT ENDOCRINOL, 3511 GV UTRECHT, NETHERLANDS
[4] FREE UNIV AMSTERDAM HOSP, DIV INTERNAL MED, 1081 HV AMSTERDAM, NETHERLANDS
[5] LEIDEN STATE UNIV, DEPT HUMAN GENET, 2312 AV LEIDEN, NETHERLANDS
来源：
ATHEROSCLEROSIS | 1990年 / 83卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：89 / 97
页数：9
相关论文
共 50 条
  • [21] THE INFLUENCE OF SIMVASTATIN ON ADRENAL CORTICOSTEROID PRODUCTION AND URINARY MEVALONATE DURING ADRENOCORTICOTROPIN STIMULATION IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    PRIHODA, JS
    PAPPU, AS
    SMITH, FE
    ILLINGWORTH, DR
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 72 (03) : 567 - 574
  • [22] APO-E POLYMORPHISM AND INSULIN LEVELS IN A BIETHNIC POPULATION
    VALDEZ, R
    DIABETES, 1994, 43 : A25 - A25
  • [23] APO-E MESSENGER-RNA AND PROTEIN-SYNTHESIS ABNORMALITIES IN A PATIENT WITH FAMILIAL PLASMA APO-E DEFICIENCY
    ZANNIS, VI
    ORDOVAS, JM
    CLADARAS, C
    SCHAEFER, EJ
    ARTERIOSCLEROSIS, 1985, 5 (05): : A503 - A503
  • [24] Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood.
    Stefanutti, C
    DiGiacomo, S
    Vivenzio, A
    Bosco, G
    Colloridi, V
    Bucci, A
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 383 - 383
  • [25] High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia
    Twickler, TB
    Dallinga-Thie, GM
    de Valk, HW
    Schreuder, PCNJ
    Jansen, H
    Cabezas, MC
    Erkelens, DW
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (11) : 2422 - 2427
  • [26] Measurement of apo AI kinetics using stable isotopes in patients with heterozygous familial hypercholesterolemia
    Frenais, R
    Ouguerram, K
    Maugeais, C
    Trouvat, AM
    DeMallmann, V
    Magot, T
    Krempf, M
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 349 - 350
  • [27] APO-E POLYMORPHISM AND CORONARY HEART-DISEASE
    KLADETZKY, RG
    MENZEL, HJ
    ASSMANN, G
    KUHN, H
    ZEITSCHRIFT FUR KARDIOLOGIE, 1982, 71 (09): : 602 - 602
  • [28] THE EFFECTS OF SIMVASTATIN ON PLASMA-LIPOPROTEINS AND CHOLESTEROL HOMEOSTASIS IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    HAGEMENAS, FC
    PAPPU, AS
    ILLINGWORTH, DR
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (02) : 150 - 157
  • [29] LONG-TERM EXPERIENCE (6 YEARS) WITH SIMVASTATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    KNOPS, RE
    KROON, AA
    MOL, MJTM
    STUYT, PMJ
    STALENHOEF, AFH
    NETHERLANDS JOURNAL OF MEDICINE, 1995, 46 (04) : 171 - 178
  • [30] Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
    McGowan, Mary P.
    Hosseini Dehkordi, Seyed Hamed
    Moriarty, Patrick M.
    Duell, P. Barton
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2019, 8 (24):
12345